Madrid, November 19, 2019.- COFIDES has subscribed Atrys company bonds worth 900.000 euro in the second issuance from the debt programme of the company dedicated to the provision of precision medical treatments and diagnostic services.  

The funds received in this second issuance, amounting to five million euro, will be allocated to the acquisition of companies that will contribute to Atrys' national and international expansion.

COFIDES also contributed in the first issuance from the Atrys bond programme last July with a subscription of bonds worth 2 million euro. In both transactions, COFIDES made the investment via the FONPYME, a fund that it manages exclusively for the Ministry of Commerce.

The COFIDES Chairman, José Luis Curbelo, has stated that subscribing bonds is in COFIDES' interest for various reasons; on the one hand, as an anchor investor, it allows middle market companies who are conducting their first issuance to reach the minimum amount, thereby generating a multiplier effect on the resources obtained by the companies; it directs the object of the bond financing towards international investments, so that the issuer is motivated to look for projects beyond Spain in addition to including in the issuance prospectuses certain commitments as regards social and environmental matters; and finally, it contributes to the development of better systems of reporting, which also improves the companies' corporate governance systems.

The ATRYS Chairman, Santiago de Torres, said that “having major public and private investors that have already participated in the first phase and wanted to do so again in this phase is a reaffirmation of the trust in our company and in our business model”.


This project contributes to the achievement of Sustainable Development Goal (3), “Health and well-being”. Atrys frequently conducts research into the development of new cancer diagnosis and treatment methods, thus contributing to the goal of reducing premature mortality from noncommunicable diseases in 2030.

Atrys focuses its activities on the provision of precision medical oncology treatments and diagnostic services, the object of which is to facilitate patients' individualised therapy, as well as the development of new therapeutic modalities and diagnostic tools. The company boasts several laboratories, equipped with the necessary facilities and technologies for diagnosis and research, located in Barcelona and Granada.

The company dedicates a significant amount of its activities to applied R&D, from which several groups of patent families have been generated in collaboration with leading national and international centres.

COFIDES is a public-private company which has been offering financial support to Spanish companies investing abroad since 1988. It is accredited with the EU to manage Community budgets, allowing it to structure transactions with a high impact on development. It is also accredited with the UN’s Green Climate Fund and can structure operations on climate change mitigation and adaptation with the GCF. It is the exclusive manager of FIEX and FONPYME funds on behalf of the Secretariat of State for Trade attached to the Ministry of Industry, Trade and Tourism and supports AECID in managing FONPRODE funds. Shareholders include Banco Santander, Banco Bilbao Vizcaya Argentaria (BBVA), Banco Sabadell and CAF-Development Bank of Latin America.